Influence of antipsychotic treatment type and regimen on the functionality of patients with schizophrenia

Nordic Journal of Psychiatry

Volumn 68, Issue 3, 2014, Pages 180-188

  Acosta, Francisco J ^a   Chinea, Eugenio ^b   Hernández, José L ^a   Rodríguez, Fernando ^c   García Bello, Miguel ^c   Medina, Gema ^d   Nieves, Wilson ^e  

^a Mental Health Research Program   (Spain)

^b HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^c HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^d HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^e HOSPITAL UNIVERSITARIO INSULAR DE GRAN CANARIA   (Spain)

Author keywords

Antipsychotics; Depot; Functionality; Injectable; Schizophrenia

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; FLUPHENAZINE; NEUROLEPTIC AGENT; NICOTINE; OLANZAPINE; PIPOTIAZINE; RISPERIDONE; ZUCLOPENTHIXOL;

ADULT; ARTICLE; DEMOGRAPHY; DISEASE SEVERITY; EDUCATIONAL STATUS; FEMALE; FUNCTIONAL STATUS; HUMAN; HUMAN RELATION; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; MIDDLE AGED; PARANOID SCHIZOPHRENIA; PATIENT COMPLIANCE; PERFORMANCE; PSYCHOPHARMACOLOGY; SELF CARE; SOCIAL BEHAVIOR; SOCIAL INTERACTION; SUBSTANCE ABUSE; TOBACCO DEPENDENCE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; OUTPATIENTS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; QUESTIONNAIRES; RISPERIDONE; SCHIZOPHRENIA; SELF CARE; SOCIOECONOMIC FACTORS; SPAIN; TREATMENT OUTCOME;

EID: 84896372543     PISSN: 08039488     EISSN: 15024725     Source Type: Journal    
DOI: 10.3109/08039488.2013.790475     Document Type: Article

References (55)

1. Tandon R, Nasrallah H a, Keshavan MS. Schizophrenia, " just the facts " 5. Treatment and prevention. Past, present, and future. Schizophr Res 2010; 122: 1-23.
2. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004; 161: 1-56.
3. Burns T, Patrick D. Social functioning as an outcome measure in schizophrenia studies. Acta Psychiatr Scand 2007; 116: 403-18.
4. Priebe S. Social outcomes in schizophrenia. Br J Psychiatry Suppl 2007; 50: s15-20.
5. Brissos S, Molodynski A, Dias VV, Figueira ML. The importance of measuring psychosocial functioning in schizophrenia. Ann Gen Psychiatry [Internet]; 2011; 10: 18. doi: 10.1186/1744-859X-10-18.
6. Novick D, Haro JM, Suarez D, Vieta E, Naber D. Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study. Schizophr Res 2009; 108: 223-30.
7. Ascher-Svanum H, Faries DE, Zhu B, Ernst FR, Swartz MS, Swanson JW. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry 2006; 67: 453-60.
8. Schennach-Wolff R, Jäger M, Seem ü ller F, Obermeier M, Messer T, Laux G, et al. Defining and predicting functional outcome in schizophrenia and schizophrenia spectrum disorders. Schizophr Res 2009; 113: 210-7.
9. Bod é n R, Sundström J, Lindström E, Lindström L. Association between symptomatic remission and functional outcome in first-episode schizophrenia. Schizophr Res 2009; 107: 232-7.
10. Ciudad A, Alvarez E, Bobes J, San L, Polavieja P, Gilaberte I. Remission in schizophrenia: Results from a 1-year follow-up observational study. Schizophr Res 2009; 108: 214-22.
11. Barnes TRE. Evidence-based guidelines for the pharmacological treatment of schizophrenia: Recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2011; 25: 567-620.
12. Siegel SJ, Irani F, Brensinger CM, Kohler CG, Bilker WB, Ragland JD, et al. Prognostic variables at intake and long-term level of function in schizophrenia. Am J Psychiatry 2006; 163: 433-41.
13. Petkari E, Salazar-Montes AM, Kallert TW, Priebe S, Fiorillo A, Raboch J, et al. Acute psychopathology as a predictor of global functioning in patients with ICD-10 non-affective psychosis: A prospective study in 11 European countries. Schizophr Res 2011; 131: 105-11.
14. Bowie CR, Depp C, McGrath J a, Wolyniec P, Mausbach BT, Thornquist MH, et al. Prediction of real-world functional disability in chronic mental disorders: A comparison of schizophrenia and bipolar disorder. Am J Psychiatry 2010; 167: 1116-24.
15. Shamsi S, Lau A, Lencz T, Burdick KE, DeRosse P, Brenner R, et al. Cognitive and symptomatic predictors of functional disability in schizophrenia. Schizophr Res 2011; 126: 257-64.
16. Hofer A, Baumgartner S, Bodner T, Edlinger M, Hummer M, Kemmler G, et al. Patient outcomes in schizophrenia II: The impact of cognition. Eur Psychiatry 2005; 20: 395-402.
17. Hofer A, Baumgartner S, Edlinger M, Hummer M, Kemmler G, Rettenbacher MA, et al. Patient outcomes in schizophrenia I: Correlates with sociodemographic variables, psychopathology, and side effects. Eur Psychiatry 2005; 20: 386-94.
18. Gonz á lez-Blanch C, Perez-Iglesias R, Pardo-Garc í a G, Rodr í guez-S á nchez JM, Mart í nez-Garc í a O, Vá zquez-Barquero JL, et al. Prognostic value of cognitive functioning for global functional recovery in first-episode schizophrenia. Psychol Med 2010; 40: 935-44.
19. Heinrichs RW, Ammari N, Miles A, McDermid Vaz S, Chopov B. Psychopathology and cognition in divergent functional outcomes in schizophrenia. Schizophr Res 2009; 109: 46-51.
20. Guo X, Zhai J, Liu Z, Fang M, Wang B, Wang C, et al. Effect of antipsychotic medication alone vs combined with psychosocial intervention on outcomes of early-stage schizophrenia: A randomized, 1-year study. Arch Gen Psychiatry 2010; 67: 895-904.
21. Penn DL, Waldheter EJ, Perkins DO, Mueser KT, Lieberman JA. Psychosocial treatment for first-episode psychosis: A research update. Am J Psychiatry 2005; 162: 2220-32.
22. Leucht C, Heres S, Kane JM, Kissling W, Davis JM, Leucht S. Oral versus depot antipsychotic drugs for schizophrenia - A critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res 2011; 127: 83-92.
23. Barnes TR, Curson DA. Long-term depot antipsychotics. A risk-benefit assessment. Drug Saf 1994; 10: 464-79.
24. Fern á ndez S á nchez A, Pinto-Meza A, Maria Haro J. Comparing the efficacy of long-acting pharmaceutical forms (depot) versus oral forms of the atypical and conventional antipsychotics marketed in Spain for treating patients with schizophrenia. Rev Psiquiatr Salud Ment (English Edition) 2009; 2: 5-28.
25. Conley RR, Ascher-Svanum H, Zhu B, Faries DE, Kinon BJ. The burden of depressive symptoms in the long-term treatment of patients with schizophrenia. Schizophr Res 2007; 90: 186-97.
26. Schennach-Wolff R, Obermeier M, Seem ü ller F, Jäger M, Messer T, Laux G, et al. Evaluating depressive symptoms and their impact on outcome in schizophrenia applying the Calgary Depression Scale. Acta Psychiatr Scand 2011; 123: 228-38.
27. Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand 2000; 101: 323-9.
28. Garcia-Portilla MP, Saiz PA, Bouso ñ o M, Bascaran MT, Guzm á n-Quilo C, Bobes J. Validaci ó n de la versi ó n espa ñ ola de la escala de Funcionamiento Personal y Social en pacientes ambulatorios con esquizofrenia estable o inestable. Rev Psiquiatr Salud Ment 2011; 4: 9-18.
29. Haro JM, Kamath SA, Ochoa S, Novick D, Rele K, Fargas A, et al. The Clinical Global Impression - Schizophrenia scale: A simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand Suppl 2003: 16-23.
30. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986; 24: 67-74.
31. Val Jim é nez A, Amor ó s Ballestero G, Mart í nez Visa P, Fern á ndez Ferr é ML, Le ó n Sanrom à M. Descriptive study of patient compliance in pharmacologic antihypertensive treatment and validation of the Morisky and Green test. [Article in Spanish]. Aten Primaria 1992; 10: 767-70.
32. Velligan DI, Weiden PJ, Sajatovic M, Scott J, Carpenter D, Ross R, et al. The expert consensus guideline series: Adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry 2009; 70 Suppl 4: 1-46; quiz 47-8.
33. Bai YM, Chen TT, Wu B, Hung CH, Lin WK, Hu TM, et al. A comparative efficacy and safety study of long-acting risperidone injection and risperidone oral tablets among hospitalized patients: 12-week randomized, single-blind study. Pharmacopsychiatry 2006; 39: 135-41.
34. Olivares JM, Rodriguez-Morales A, Diels J, Povey M, Jacobs A, Zhao Z, et al. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: Results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur Psychiatry 2009; 24: 287-96.
35. Barnes TRE, Paton C. Antipsychotic polypharmacy in schizophrenia: Benefits and risks. CNS Drugs 2011; 25: 383-99.
36. Joukamaa M, Heliövaara M, Knekt P, Aromaa A, Raitasalo R, Lehtinen V. Schizophrenia, neuroleptic medication and mortality. Br J Psychiatry 2006; 188: 122-7.
37. Misawa F, Shimizu K, Fujii Y, Miyata R, Koshiishi F, Kobayashi M, et al. Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: A cross-sectional study. BMC Psychiatry 2011; 11: 118.
38. Garc í a B. Functionality as a goal in the treatment of schizophrenia. [Article in Spanish]. Actas Esp Psiquiatr 2002; 30: 312-25.
39. Leucht S, Kissling W, Davis JM. Second-generation antipsychotics for schizophrenia: Can we resolve the conflict? Psychol Med 2009; 39: 1591-602.
40. Leucht S, Heres S. Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia. J Clin Psychiatry 2006; 67 (Suppl 5) : 3-8.
41. Chakos M, Patel JK, Rosenheck R, Glick ID, Hammer MB, Tapp A, et al. Concomitant psychotropic medication use during treatment of schizophrenia patients: Longitudinal results from the CATIE study. Clin Schizophr Relat Psychoses 2011; 5: 124-34.
42. Jin H, Zisook S, Palmer BW, Patterson TL, Heaton RK, Jeste DV. Association of depressive symptoms with worse functioning in schizophrenia: A study in older outpatients. J Clin Psychiatry 2001; 62: 797-803.
43. Deister A, Marneros A. Prognostic value of initial subtype in schizophrenic disorders. Schizophr Res 1994; 12: 145-57.
44. Lambert M, De Marinis T, Pfeil J, Naber D, Schreiner A. Establishing remission and good clinical functioning in schizophrenia: Predictors of best outcome with long-term risperidone long-acting injectable treatment. Eur Psychiatry 2010; 25: 220-9.
45. Swanson CL, Gur RC, Bilker W, Petty RG, Gur RE. Premorbid educational attainment in schizophrenia: Association with symptoms, functioning, and neurobehavioral measures. Biol Psychiatry 1998; 44: 739-47.
46. Flor-Henry P. Influence of gender in schizophrenia as related to other psychopathological syndromes. Schizophr Bull 1990; 16: 211-27.
47. Goldstein JM, Tsuang MT, Faraone SV. Gender and schizophrenia: Implications for understanding the heterogeneity of the illness. Psychiatry Res 1989; 28: 243-53.
48. Dixon L. Dual diagnosis of substance abuse in schizophrenia: Prevalence and impact on outcomes. Schizophr Res 1999; 35 Suppl: S93-100.
49. Aguilar MC, Gurpegui M, Diaz FJ, de Leon J. Nicotine dependence and symptoms in schizophrenia: Naturalistic study of complex interactions. Br J Psychiatry 2005; 186: 215-21.
50. Smith RC, Singh A, Infante M, Khandat A, Kloos A. Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia. Neuropsychopharmacology 2002; 27: 479-97.
51. Winterer G. Why do patients with schizophrenia smoke? Curr Opin Psychiatry 2010; 23: 112-9.
52. Sacco KA, Termine A, Seyal A, Dudas MM, Vessicchio JC, Krishnan-Sarin S, et al. Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: Involvement of nicotinic receptor mechanisms. Arch Gen Psychiatry 2005; 62: 649-59.
53. Wing VC, Bacher I, Sacco K a, George TP. Neuropsychological performance in patients with schizophrenia and controls as a function of cigarette smoking status. Psychiatry Res 2011; 188: 320-6.
54. Sagud M, Mihaljevi-Peles A, Mü ck-Seler D, Pivac N, Vuksan-Cusa B, Brataljenovi T, et al. Smoking and schizophrenia. Psychiatr Danub 2009; 21: 371-5.
55. Kotov R, Guey LT, Bromet EJ, Schwartz JE. Smoking in schizophrenia: Diagnostic specificity, symptom correlates, and illness severity. Schizophr Bull 2010; 36: 173-81.